BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/3/2015 12:01:00 PM | Browse: 1433 | Download: 2269
Publication Name World Journal of Hepatology
Manuscript ID 13540
Country Taiwan
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Current systemic treatment of hepatocellular carcinoma: A review of the literature
Manuscript Source Invited Manuscript
All Author List Kai-Wen Chen, Tzu-Ming Ou, Chin-Wen Hsu, Chi-Ting Horng, Ching-Chang Lee, Yuh-Yuan Tsai, Chi-Chang Tsai, Yi-Sheng Liou, Chen-Chieh Yang, Chao-Wen Hsueh and Wu-Hsien Kuo
Funding Agency and Grant Number
Corresponding Author Wu-Hsien Kuo, MD, PhD, Professor, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, No.2, Zhongzheng 1st Rd., Lingya District, Kaohsiung 80284, Taiwan. wuhsienku@gmail.com
Key Words Hepatocellular carcinoma; Transarterial chemoembolization; Sorafenib; Systemic treatment; Molecular target therapy
Core Tip Sorafenib is a multi-targeted tyrosine kinase inhibitor that was the first systemic therapy in the world to improve the survival rate of patients with advanced hepatocellular carcinoma (HCC) in a phase Ⅲ trial. However, the overall outcomes are sometimes unsatis-factory and there is a need for second line therapies in patients with advanced HCC who still progress after the use of sorafenib. Novel systemic approaches are needed in advanced HCC.
Publish Date 2015-06-03 12:00
Citation Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015; 7(10): 1412-1420
URL http://www.wjgnet.com/1948-5182/full/v7/i10/1412.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i10.1412
Full Article (PDF) WJH-7-1412.pdf
Full Article (Word) WJH-7-1412.doc